Navigation Links
Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for 'Click Chemistry'
Date:4/17/2013

HUNTSVILLE, Ala., April 17, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has entered into a worldwide exclusive license agreement with The Scripps Research Institute for "click chemistry" – a facile method of attaching molecules together in a precise and quantitative manner. Further details of the agreement and the financial terms were not disclosed.

"Click chemistry represents a major advance in how small molecules can be 'clicked' together," said Dr. Mike Bentley , Chief Scientific Officer of Serina Therapeutics. "This license agreement allows us to attach small molecules to POZ polymers in a precise, quantitative and reproducible manner, and that is critical to our drug development efforts."

Click chemistry was invented by Professor Barry Sharpless at The Scripps Research Institute. Dr. Sharpless shared the Nobel Prize in Chemistry in 2001 for his groundbreaking work in unraveling chiral catalysts.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit their website at http://www.serinatherapeutics.com

About Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2020)... ... January 09, 2020 , ... R3 Stem Cell, the ... freezer program. The cryogenic freezer allows practices to have plenty of stem cell ... exosome biologics require cryogenic freezing. This may include a practice receiving the biologics ...
(Date:1/7/2020)... ... January 07, 2020 , ... Ironsphere, ... service providers, announced today it has been selected by MetLife Stadium for Privileged ... , “As part of our ongoing commitment to maintain the highest of security ...
(Date:1/7/2020)... TORONTO (PRWEB) , ... January 06, 2020 , ... Myant ... that enable continuous and ambient heart health management at CES 2020 (January 7-10, Las ... as a winner in the Health & Wellness category of the CES 2020 Innovation ...
Breaking Medicine Technology:
(Date:1/23/2020)... ... January 23, 2020 , ... DelawareBio, a nonprofit trade ... a panel discussion on gene editing that goes beyond CRISPR technology. To be ... Education Center, the event will provide an overview of the opportunities and challenges ...
(Date:1/23/2020)... ... January 23, 2020 , ... Three leading healthcare organizations, ... to improve diagnostic quality and safety by joining the Coalition to Improve ... healthcare and patient advocacy. , “Diagnostic error is one of the most important ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... ... and risk services for organizations that operate vehicle fleets in North America and ... subscriber-based e-newsletter, will be published monthly with content accessible on the company’s website. ...
(Date:1/23/2020)... Texas (PRWEB) , ... January 23, 2020 , ... ... announced a strategic partnership using SocialClimb’s innovative technology to power the Arrowlytics platform ... practice efficiency and profitability. SocialClimb’s platform integrates seamlessly with practice management systems to ...
(Date:1/22/2020)... (PRWEB) , ... January 22, ... ... cloud-based ambulatory EHR , revenue cycle management services, integrated practice management, ... System, Hospital Information Management System and Personal Health Record for Indian healthcare ...
Breaking Medicine News(10 mins):